EGFR and non-small cell lung carcinoma: In the ADAURA phase III trial [34], 682 patients with completely resected stage IB-IIIA NSCLC who presented common EGFR mutations (Ex19del or L858R) were randomized to receive osimertinib 80 mg daily or a placebo for up to 3 years, with the option of adjuvant chemotherapy based on the stage of their disease.